GSK, PATH, and Bharat Biotech (BBIL) today announced the signing of a product transfer agreement for the malaria vaccine, RTS,S/AS01E. The agreement includes the transfer of manufacturing of the RTS,S antigen part of the vaccine and the grant of a license on all rights pertaining to the RTS,S/AS01 malaria vaccine to BBIL.
Given the constant threat of malaria in Malawi, parents and caregivers of young children must pay close attention to strategies for preventing the disease. Lusitana and Evison were born at the tail end of 2018, at a time of year when the rainy season amps up and the risk for transmission of the malaria parasite increases. The recommended tools that have been available to stave off infection include mosquito nets, indoor spraying with insecticides, and anti-malarial medicines. In 2019, a vaccine was added to this malaria toolkit in selected parts of the country.
Researchers at the Ragon Institute of MGH, MIT and Harvard, in collaboration with the global health non-profit PATH, the Walter Reed Army Institute of Research, and pharmaceutical companies GSK and Janssen Vaccines & Prevention B.V., have discovered two markers of immunity in response to the RTS,S/AS01 malaria vaccine that correlated strongly with protection from infection. The ability to identify a successful immune response to the RTS,S/AS01 vaccine could greatly reduce the amount of time and funding needed to develop more effective malaria vaccines.
The partnership that developed the RTS,S malaria vaccine—the world’s first malaria vaccine—was the Global Health Technology Coalition’s 2019 Innovating for Impact Partnership Award honoree. This partnership was led by GSK and PATH—and now in collaboration with the World Health Organization—with critical contributions from the Walter Reed Army Institute of Research, other US agencies, and countless partners.
Washington, DC, November 13, 2019 - PATH and partners today received the Global Health Technologies Coalition (GHTC) 2019 Innovating for Impact Partnership Award, for the development and phased introduction of RTS,S/AS01, the world’s first malaria vaccine. The vaccine was introduced by ministries of health in areas of Ghana, Kenya, and Malawi in 2019 as part of a pilot program coordinated by the World Health Organization (WHO).
In recent years, Kenya has made tremendous progress in the fight against malaria through the scale-up of insecticide-treated mosquito nets (ITNs), indoor residual spraying (IRS), and appropriate diagnosis and treatment, using artemisinin-based combination therapies (ACTs).
Seattle, WA, September 13, 2019 – PATH congratulates Kenya as it joins Ghana and Malawi in providing the world’s first malaria vaccine to children through routine immunization. With the start of vaccination in Kenya, the World Health Organization (WHO)-coordinated Malaria Vaccine Implementation Programme (MVIP) is now fully underway.
Seattle, WA, April 23, 2019 – PATH welcomes the announcement today by the World Health Organization (WHO) and the Malawi Ministry of Health that the first children have received the RTS,S/AS01 (RTS,S) malaria vaccine through routine immunization in Malawi, marking the beginning of a pilot introduction of the vaccine. Malawi is the first of the three participating countries—the others being Ghana and Kenya—to begin vaccination.
Imagine if scientists could create their own antibodies – the protein that the immune system creates in order to fight diseases. While it might sound like something out of a science fiction novel, scientists have figured out a way to do it. What is the benefit of producing such a thing? These monoclonal antibodies or mAbs give scientists the ability to target a specific antigen – possibly making it easier to treat some of the world’s toughest diseases.